ACCELERON PHARMA INC
DelistedCIK 1280600fmd_02F8HBW31SR54NP9Q3KTFDN0D2Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2011 to Sep 30, 2021, 40 periods
| Line item | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 81 | 15 | 57 | 15 | 18 | 28 | 13 | 14 | 74 | 93 |
| Research and development | 33 | 35 | 36 | 51 | 58 | 69 | 90 | 104 | 154 | 174 |
| Selling, general and administrative | – | – | – | – | – | – | 34 | 35 | 56 | 86 |
| Operating income | 39 | (29) | 7 | (55) | (61) | (66) | (110) | (124) | (136) | (167) |
| Interest expense | 2 | 2 | 2 | 1 | 0 | 0 | – | – | – | – |
| Interest and investment income | 0 | 0 | 0 | 0 | 1 | 2 | 3 | 6 | – | – |
| Other non-operating income (expense) | (2) | (4) | (29) | 4 | (3) | 9 | 2 | 6 | 12 | 1 |
| Income before taxes | 36 | (33) | (22) | (51) | (64) | (57) | (108) | (119) | (125) | (166) |
| Income tax expense | – | – | – | 0 | 0 | 0 | 0 | (0) | (0) | 0 |
| Net income from continuing operations | – | – | – | (51) | (64) | (57) | (108) | (119) | (125) | (166) |
| Net income | 36 | (33) | (22) | (51) | (64) | (57) | (108) | (119) | (125) | (166) |
| Net income to common shareholders | 2 | (60) | (39) | (51) | (64) | – | – | – | – | – |